Adenomyosis and Overseas IVF: Indications, Examinations, and Process Analysis

AI Summary

Main Content Begins

Clinical Decision Logic: As a practitioner in reproductive medicine, I often encounter patients with adenomyosis in outpatient clinics asking about the feasibility of overseas IVF. The answer is not uniform but based on a comprehensive assessment of lesion characteristics, ovarian reserve, previous treatment history, and patient age. The decision-making path usually begins with a clear diagnosis and classification, rather than directly entering an IVF cycle. The following content is based on clinical observations and industry consensus for patient reference.

1. Direct Answer: Can Patients with Adenomyosis Undergo Overseas IVF?

Patients with adenomyosis can travel abroad for IVF, but only after thorough medical evaluation and necessary pretreatment. Whether they are suitable for an IVF cycle mainly depends on the following four dimensions:

• Lesion Type and Extent: Mild diffuse adenomyosis (uterine volume < 10 weeks gestation, myometrial thickness < 3 cm) usually allows direct entry into the IVF process; localized adenomyosis or adenomyoma (diameter > 3 cm) requires assessment of its impact on uterine cavity shape.
• Endometrial Receptivity: Adenomyosis lesions can lead to reduced subendometrial blood flow and elevated inflammatory factors, affecting embryo implantation. Before transfer, endometrial status should be evaluated using 3D ultrasound, uterine artery Doppler, ERA testing, and other methods.
• Ovarian Reserve: Age, AMH, and antral follicle count are core indicators of ovarian response. If ovarian reserve is diminished, both lesion control and oocyte retrieval efficiency must be considered.
• Previous Treatment Response: The degree of lesion shrinkage after previous GnRH-a use and past IVF transfer outcomes are important references for determining the effectiveness of subsequent protocols.

When the above conditions are met and after standardized pretreatment, overseas IVF can be a viable option for patients with adenomyosis to achieve pregnancy.

2. Doctor's Perspective: How Adenomyosis Affects IVF Outcomes

From a reproductive medicine standpoint, adenomyosis affects fertility mainly through the following three pathways:

• Uterine Cavity Microenvironment Disruption: Repeated bleeding and inflammation from ectopic endometrial glands within the myometrium lead to abnormal cytokine profiles in the uterine cavity, such as elevated IL-6 and TNF-α, interfering with embryo implantation.
• Uterine Hemodynamic Changes: Vascular proliferation and increased vascular resistance in the lesion area reduce subendometrial blood flow, affecting nutritional supply after embryo implantation.
• Decreased Endometrial Receptivity: The implantation window may be shifted in adenomyosis patients. ERA testing shows that approximately 30-40% of patients have abnormal endometrial receptivity, requiring individualized adjustment of transfer timing.

3. Age-Related Differences: Decision-Making and Protocol Adjustments

Age is an independent factor influencing IVF outcomes in adenomyosis patients. Ovarian reserve, lesion characteristics, and treatment strategies vary significantly across age groups.

It is worth noting that adenomyosis patients over 40 face dual challenges in overseas IVF—the impact of lesions on the endometrium combined with declining egg quality. At this stage, it is advisable to choose a fertility center with extensive experience in both adenomyosis management and advanced maternal age treatment.

4. Country-Specific Medical Differences: How to Choose an Overseas Center

Management strategies for adenomyosis vary among fertility centers in different countries and regions, mainly reflected in the following aspects:

When selecting an overseas fertility center, it is recommended to focus on its experience with complex adenomyosis cases, availability of ERA testing, frozen embryo transfer success rates, and multidisciplinary collaboration capabilities (reproductive medicine + radiology + gynecological surgery team).

5. Practical Process: Seven Steps for Adenomyosis Patients Undergoing Overseas IVF

The overseas IVF process for adenomyosis patients is largely similar to conventional IVF, but requires more rigorous attention to detail. The standard process is as follows:

1. Domestic Pre-Assessment (1-2 weeks): Complete pelvic MRI, 3D ultrasound, hormone panel, AMH, CA125, HE4, thyroid function, coagulation function, etc. Bring complete medical records.
2. Overseas Initial Consultation and Protocol Formulation (1-2 days): Face-to-face consultation with a reproductive specialist, review of test results, determination of whether pretreatment is needed and the pretreatment protocol (GnRH-a injections for 2-6 months).
3. Pretreatment Phase (2-6 months): Follow medical advice for GnRH-a injections every 28 days. Monitor uterine volume, CA125 changes, and symptom improvement during this period.
4. Ovarian Stimulation Phase (10-14 days): Mostly use ultra-long or long protocols. Monitor follicular development and perform oocyte retrieval at the appropriate time. Blastocyst culture and freezing of all embryos are recommended for adenomyosis patients.
5. Endometrial Preparation and Transfer Decision (1-2 months): Before frozen embryo transfer, reassess endometrial status (3D ultrasound + uterine artery Doppler). Perform ERA testing if necessary to determine the window of implantation.
6. Embryo Transfer (1 day): Perform single blastocyst transfer during the window of implantation. Start luteal phase support immediately after transfer (dydrogesterone + progesterone injections or vaginal gel).
7. Post-Transfer Management (pregnancy test after 14 days): Check blood HCG 12-14 days after transfer. If pregnancy is confirmed, continue luteal phase support until 10-12 weeks of gestation. Monitor for abdominal pain and vaginal bleeding.

6. Case Scenario Analysis: Three Typical Situations

Scenario 1: 32 years old, mild diffuse adenomyosis, AMH 3.2, no previous IVF history
This patient has good ovarian reserve and mild lesions, so she can directly enter an IVF cycle. Use a long protocol for stimulation, retrieve 12-15 oocytes, form 6-8 blastocysts. Before frozen embryo transfer, use GnRH-a down-regulation for 2 months, prepare the endometrium with an artificial cycle, and provide standard luteal phase support after transfer. The live birth rate per single transfer is approximately 45-55%.

Scenario 2: 38 years old, moderate adenomyosis with adenomyoma (diameter 3.5 cm), AMH 1.8, one previous failed transfer
Recommend GnRH-a treatment for 4 months first. Follow-up MRI shows lesion shrinkage to 2.2 cm and uterine volume reduction by 30%. Then proceed with ovarian stimulation, retrieve 9 oocytes, form 4 blastocysts. ERA testing before transfer indicates a 24-hour delay in the window of implantation. Transfer is performed at the adjusted time, resulting in a successful pregnancy.

Scenario 3: 43 years old, severe diffuse adenomyosis, AMH 0.6, with stage III endometriosis
Ovarian reserve is poor, and egg quality is declining. Recommend first retrieving oocytes to accumulate embryos (over 2-3 cycles), while undergoing GnRH-a pretreatment for 6 months. After uterine volume reduction, perform frozen embryo transfer. PGT-A screening is recommended before transfer. The live birth rate in this situation is low (approximately 10-15%), so realistic expectations are necessary.

7. Special Situations: What to Do When Combined with Other Pathologies

Adenomyosis often coexists with other gynecological conditions, requiring comprehensive management:

• Combined with Adenomyoma: If the lesion diameter is > 4 cm and affects uterine cavity shape, laparoscopic lesion resection is recommended, followed by GnRH-a for 3 months before entering an IVF cycle.
• Combined with Endometriosis: The two conditions often coexist. Post-surgery, use GnRH-a for 3-6 months to control both conditions simultaneously before proceeding with IVF.
• Combined with Hydrosalpinx: Fluid reflux into the uterine cavity can affect embryo implantation. The hydrosalpinx must be treated first (laparoscopic salpingectomy or proximal tubal occlusion) before transfer.
• Combined with Ovarian Cyst: If the cyst diameter is > 5 cm or suspicious for malignancy, surgical treatment is needed first, taking care to preserve ovarian reserve.
• Combined with Uterine Fibroids: Submucosal fibroids or intramural fibroids compressing the endometrium should be surgically treated first; subserosal fibroids that do not affect the cavity can allow IVF to proceed first.

For protocol selection in special situations, it is recommended that a reproductive specialist and a gynecological surgeon jointly evaluate and develop a phased treatment plan.

8. Frequently Asked Questions

Q1: What is the approximate success rate of overseas IVF for adenomyosis?
The success rate is directly related to lesion severity, age, and ovarian reserve. For mild adenomyosis in patients under 35, the live birth rate per single transfer is about 40-50%; for moderate adenomyosis in patients aged 36-40, the live birth rate is about 25-35%; for severe adenomyosis or patients > 40, the live birth rate is about 10-20%. These figures are clinical observation references, and individual variation is significant.

Q2: Is surgery necessary before IVF for adenomyosis?
Not necessarily. Diffuse adenomyosis is primarily treated with medication (GnRH-a); localized adenomyosis or adenomyoma affecting uterine cavity shape may require surgery. The final plan depends on the lesion type and uterine volume.

Q3: What precautions should be taken after embryo transfer for adenomyosis patients?
After transfer, pay attention to: ① Take luteal phase support medications on time without missing doses; ② Avoid strenuous exercise and prolonged standing; ③ Monitor for abdominal pain and vaginal bleeding; seek medical attention if persistent pain or bright red bleeding occurs; ④ Maintain regular bowel movements to avoid increased abdominal pressure.

Q4: What additional documents do adenomyosis patients need to prepare for overseas IVF?
In addition to standard documents (passport, visa, marriage certificate, birth certificate, etc.), it is recommended to bring: pelvic MRI or 3D ultrasound reports, CA125 and HE4 test reports, previous surgical records (if any), and records of previous IVF cycles (if any).